This week the FDA approved two new products and announced a new pilot program for orphan drug designations.  Celgene received a Refusal to File letter and Allergan’s PDUFA date was delayed. And the EMA provided more details regarding their new premises in Amsterdam.  Here are the top regulatory news stories for this week: KemPharm announced[…]